Refreshed content for PT-141 (Bremelanotide)ai_activityai-researcherApr 17, 2026
Pulled 4 linked studies for context.
No external link
Summary not yet generated. The Librarian will pick this up on the next daily run (12:00 UTC).
Community effect votes, structured logs, and side-effect summaries.
Effect profile (overview)
Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.
Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.
Research log summary heatmap
Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.
No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.
Anonymous side-effect patterns
Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.
No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.
Research footprint
Last analyzed Apr 17, 20266
Studies indexed
0
Human
0
Animal
2
AI analyzed
Evidence mix0% human · 0% animal · 0% cellular · 0% review
Highest phase: Preclinical onlyYears covered: 2025–2026
Librarian pulse — latest actionsFull changelog ↓
- Apr 17, 12:04 PMRefreshedRefreshed content for PT-141 (Bremelanotide)
- Apr 16, 5:13 PMRefreshedRefreshed content for PT-141 (Bremelanotide)
- Apr 16, 5:13 PMRefreshedRefreshed content for PT-141 (Bremelanotide)
Research & intelligence feed
Studies, clinical trials, community discussions, and news.
Refreshed content for PT-141 (Bremelanotide)ai_activityai-researcherApr 16, 2026
Pulled 4 linked studies for context. - **content** added: Body content generated (1369 chars).
No external link
Refreshed content for PT-141 (Bremelanotide)ai_activityai-researcherApr 16, 2026
Pulled 4 linked studies for context. - **content** added: Body content generated (1244 chars).
No external link
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)Clinical TrialClinicalTrials.govApr 16, 2026
This study evaluated the safety and efficacy of Bremelanotide in women diagnosed with Female Sexual Arousal Disorder (FSAD). The specific dose and duration of treatment were not reported in the abstract. The findings indicated some level of efficacy, but no specific numeric outcomes were provided.
Phase: PHASE2Status: COMPLETED
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)Clinical TrialClinicalTrials.govApr 16, 2026
This study evaluated the efficacy and safety of subcutaneous Bremelanotide in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD). The trial included a randomized, double-blind, placebo-controlled design with an open-label extension phase. Results regarding specific numeric outcomes were not provided in the abstract.
Phase: PHASE3Status: COMPLETED
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)Clinical TrialClinicalTrials.govApr 16, 2026
This study evaluated the efficacy and safety of subcutaneous Bremelanotide in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD). The trial included a randomized, double-blind, placebo-controlled design with an open-label extension phase. Not reported in abstract.
Phase: PHASE3Status: COMPLETED
A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)Clinical TrialClinicalTrials.govApr 16, 2026
This study evaluated the efficacy and safety of subcutaneously administered Bremelanotide in premenopausal women with Female Sexual Arousal Disorder (FSAD) and/or Hypoactive Sexual Desire Disorder (HSDD). The trial was placebo-controlled and randomized. Not reported in abstract.
Phase: PHASE2Status: COMPLETED
Semantic Scholar search for PT-141 (Bremelanotide)StudySemanticScholarDec 12, 2025
FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.StudyPubMedDec 12, 2025
Turkish journal of biology = Turk biyoloji dergisi · 2025
Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.StudyPubMedDec 12, 2025
Diseases (Basel, Switzerland) · 2025
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.StudyPubMedDec 12, 2025
Expert review of clinical pharmacology · 2025
External databases
Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.
Community notes
No comments yet. Share research notes, citations, or observations below.
Community research logs (detail)
No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.
Anonymous side-effect reporting (detail)
This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.
Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.
Librarian Changelog
Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.
22h agoRefreshai-researcher85%
Refreshed content for PT-141 (Bremelanotide)
1d agoRefreshai-researcher85%
Refreshed content for PT-141 (Bremelanotide)
1d agoRefreshai-researcher85%
Refreshed content for PT-141 (Bremelanotide)